Lexicon Advances Non-Opioid Pain Med to Phase III Following Post-Hoc Analysis
Lexicon Pharmaceuticals (NASDAQ:LXRX) is moving forward with Phase III trials for its non-opioid pain medication, pilavapadin, despite a topline miss earlier this year. Analysts at Jefferies attribute this decision to an “improving” regulatory environment favoring non-addictive treatments for chronic pain.
In March, the Texas-based biotech announced that pilavapadin would advance to late-stage development, even though the drug failed to show significant pain reduction in its Phase IIb PROGRESS trial. On Wednesday, Lexicon unveiled new post-hoc data to support its decision, presented at the 2025 European Association for the Study of Diabetes meeting.
The updated analysis excluded the 20-mg dose arm, which had been blamed for the lack of significant results in the original topline readout. Instead, the post-hoc findings focused on a 10-mg daily dose, which demonstrated “nominally significant separation from placebo” in pain improvement. Lexicon has identified this dose as the “most clinically meaningful” to carry into Phase III trials. Additionally, the analysis revealed a “clinically meaningful” reduction in average daily pain after 11 weeks of treatment.
Jefferies analysts noted that these findings provide “evidence of an efficacy signal” sufficient to justify late-stage development. They also highlighted the FDA’s recent efforts to streamline the approval process for non-opioid pain treatments as a key factor supporting Lexicon’s decision. Last week, the FDA released draft guidelines allowing for a “single adequate and well-controlled” trial, supplemented by confirmatory evidence, to serve as the basis for drug approval. The agency also encouraged the exploration of biomarkers that could qualify drugs for expedited review programs, such as fast track or breakthrough designations.
“The FDA is collaborating closely with sponsors who are developing non-addictive alternatives,” Jefferies wrote, adding that pivotal studies for pilavapadin could begin by the end of this year or early 2026, with topline results expected between 2027 and 2028. The firm projects blockbuster potential for pilavapadin, estimating its market value at over $1 billion.
Despite the promising data, Jefferies analysts cautioned that replicating these results in Phase III remains uncertain. They also noted that pilavapadin has not yet been tested for 12 weeks, a study duration preferred by the FDA.
As the regulatory landscape continues to evolve, Lexicon’s pilavapadin could play a significant role in addressing the unmet need for non-addictive chronic pain treatments.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions. Using a patient driven approach, we are working to discover and develop innovative medicines to safely and effectively treat disease and improve patient lives.
